Allelic loss on chromosome 13 occurs frequently in esophageal squamous cell carcinomas. To define minimal deletion intervals and find candidate tumor suppressor gene(s), we conducted a study of loss of heterozygosity (LOH) in 59 esophageal squamous cell carcinomas from northern China using a panel of ten microsatellite markers on chromosome 13q. The results showed that 12 of 59 (20%) cases presented allelic loss in three or more consecutive adjacent chosen markers, suggesting loss of larger fragments on chromosome 13q. Two minimal deletion regions of overlap were found: one was located on band 13q12.3 from markers D13S171 to D13S267, and the other on band 13q14.1-q14.3 from markers D13S263 to D13S168. The latter was a new deletion region that was never reported in esophageal squamous cell carcinomas. More frequent LOH was observed in higher pathological grade of esophageal cancer at loci D13S171, D13S263 and in later stage of esophageal cancer at D13S263. The data suggest the possibility that one or more unknown tumor suppressor gene(s) on 13q may play an important role in the development of esophageal squamous cell carcinomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0304-3835(02)00234-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
Clin Transl Oncol
March 2025
Pathology Department, Hospital del Mar, Pompeu Fabra University, Hospital del Mar Research Institute, Barcelona, Spain.
Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA.
View Article and Find Full Text PDFLncRNA-DANCR Promotes ESCC Progression and Function as ceRNA to Regulate DDIT3 Expression by Sponging microRNA-3193.
Cancer Sci
March 2025
Translational Medicine Research Center, Department of Pathology & Shanxi Key Laboratory of Carcinogenesis and Translational Research of Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of cancer development and progression. Among them, Differentiation Antagonizing Non-Protein Coding RNA (DANCR) has been implicated in various malignancies, including esophageal squamous cell carcinoma (ESCC). This study explores the clinical characteristics, prognostic implications, functional roles, and molecular mechanisms of DANCR in ESCC.
View Article and Find Full Text PDFCENP-H as a new prognostic biomarker for tumors: a real-world literature review.
Front Oncol
February 2025
Department of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Centromere protein H (CENP-H) is an important component of a functional centromere. Studies have demonstrated that CENP-H is overexpressed in renal cell, gastric, hypopharyngeal squamous cell, nasopharyngeal, endometrial, lung, cervical, esophageal, liver, colorectal, oral squamous cell, breast, and tongue carcinomas. CENP-H overexpression is positively correlated with a poor prognosis, pathological stage, T stage, and lymph node metastasis in patients with the above carcinomas.
View Article and Find Full Text PDFPotential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics.
BMC Cancer
March 2025
Central Laboratory, School of Medicine, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, 361102, P.R. China.
Background: Esophageal squamous cell carcinoma (ESCC), the most common type of esophageal cancer, characterized by low five-year survival rate, and concurrent chemoradiotherapy (CCRT) has been proposed to treat ESCC, while potential biomarkers for prognostic monitoring after optimized CCRT remains unknown.
Methods: Serum samples from 45 patients with ESCC were collected and categorized into three groups: Control (pre-CCRT), CCRT (during CCRT), and CCRT-1 M (one-month post-CCRT). The therapeutic effect was evaluated using CT imaging and established evaluation criteria.
STAT3-orchestrated gene expression signatures and tumor microenvironment in esophageal squamous cell carcinoma uncovered by single-cell sequencing.
Biochim Biophys Acta Gen Subj
March 2025
Department of Oncology, Wujin Hospital Affiliated with Jiangsu University, Changzhou 213000, Jiangsu, China; Department of Oncology, The Wujin Clinical college of Xuzhou Medical University, Changzhou 213000, Jiangsu, China.
Background: The progression of Esophageal Squamous Cell Carcinoma (ESCC) can be dissected with greater precision using multi-omics and single-cell RNA sequencing (scRNA-seq) compared to traditional methodologies. These advanced approaches enable a comprehensive understanding of cellular heterogeneity and molecular dynamics, offering higher resolution insights into cancer development. Moreover, analyzing transcription factor regulatory networks provides innovative avenues for identifying cancer biomarkers and therapeutic targets, driving new perspectives in cancer research.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!